Reporting owner · CIK 0001339375
Riley Antony A
Visual SEC Form 4 history across 1 companies, 22 transactions and 4 filings.
CFOCHIEF FINANCIAL OFFICERForte Biosciences, Inc.
Open-market mix
100%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.
- Window follows the rest of the summary (all-history or last 3 months).
- Only buys with a resolved price context are counted.
- Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 24
$0
Jan 25
$0
Dec 25
$254.8K
Jan 26
$0
Aug 26
$0
Transaction texture
Ownership and ticket size
Average P/S size$254.8K
Median P/S size$254.8K
Direct22
Indirect0
Aug 27, 2026return
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
buy at Forte Biosciences, Inc. on Dec 30, 2025 valued at $254,833.
Review SEC filingLatest sale
No open-market insider sale is available.
Associated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| FBRX | Riley Antony A | CFO | return | 421 | — | D | — | 08/27 | 08/27 | |
| FBRX | Riley Antony A | CFO | unknown | 42.6k | — | U | — | 08/27 | 08/27 | |
| FBRX | Riley Antony A | CFO | exercise | 375 | $0 | M | +5.3% | 01/02 | 01/01 | |
| FBRX | Riley Antony A | CFO | withholding | 154 | -$419k | F | +5.3% | 01/02 | 01/01 | |
| FBRX | Riley Antony A | CFO | exercise | 375 | $0 | M | +5.3% | 01/02 | 01/01 | |
| FBRX | Riley Antony A | CFO | buy | 9.68k | $25.4M | P | +5.3% | 01/02 | 12/30/2025 | |
| FBRX | Riley Antony A | CFO | exercise | 375 | $0 | M | — | 01/02/2025 | 01/01/2025 | |
| FBRX | Riley Antony A | CFO | withholding | 154 | -$349k | F | — | 01/02/2025 | 01/01/2025 | |
| FBRX | Riley Antony A | CFO | exercise | 375 | $0 | M | — | 01/02/2025 | 01/01/2025 | |
| FBRX | Riley Antony A | CFO | exercise | 9.37k | $0 | M | — | 01/03/2024 | 01/01/2024 |
Riley Antony A Insider Activity FAQ
SEC Form 4 context
Who is Riley Antony A?
Riley Antony A is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001339375.
Which companies has Riley Antony A reported transactions for?
Forte Biosciences, Inc.
When was Riley Antony A's latest insider buy?
buy at Forte Biosciences, Inc. on Dec 30, 2025 valued at $254,833.
When was Riley Antony A's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.